In a statement published in early April, EMA announced its collaboration with TGA on creating better access to orphan drugs. In the statement, EMA noted that “the two regulators have agreed to share the full assessment reports related to marketing authorisations of orphan medicines.” The statement goes on to note that this strengthens pre-exisiting collaborations, such as those involved in GMPs.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
